Y-MABS THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.36 USD | -3.20% |
|
-3.90% | +113.20% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Y-mAbs Therapeuti...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
14.84
USD
Average target price
21.67
USD
Spread / Average Target
+46.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +113.20% | 650M | |
| -2.18% | 103B | |
| +0.37% | 95.71B | |
| +2.30% | 22.02B | |
| -16.78% | 20.9B | |
| -9.30% | 17.85B | |
| -42.83% | 16.21B | |
| -14.97% | 15.52B | |
| +3.94% | 13.86B | |
| +34.63% | 12.04B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Transcript : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
